Abstract
Pancreatic adenocarcinoma has an extremely poor prognosis. With the best available treatments, the median overall survival duration is still less than 1 year. Most patients develop anorexia and major muscle mass loss that interfere with chemotherapy tolerance and survival. In this paper, we present a case in which these problems were a major concern. A multidisciplinary approach with chemotherapy and close nutritional support permitted better control of the disease and longer survival. We also review the literature on nutritional interventions that show an improvement in quality of life and survival in these patients.
MeSH terms
-
Aged
-
Alanine Transaminase / blood
-
Anthropometry
-
Antigens, Tumor-Associated, Carbohydrate / blood
-
BRCA2 Protein / genetics
-
BRCA2 Protein / metabolism
-
Blood Glucose / metabolism
-
Body Mass Index
-
C-Reactive Protein / metabolism
-
Carcinoembryonic Antigen / blood
-
Creatinine / blood
-
Fatty Acids, Omega-3 / therapeutic use*
-
Follow-Up Studies
-
Humans
-
Male
-
Muscle, Skeletal / drug effects*
-
Muscle, Skeletal / physiopathology
-
Nutritional Support
-
Pancreatic Neoplasms / diagnosis*
-
Pancreatic Neoplasms / drug therapy*
-
Prognosis
-
Quality of Life
-
Serum Albumin / metabolism
-
gamma-Glutamyltransferase / blood
Substances
-
Antigens, Tumor-Associated, Carbohydrate
-
BRCA2 Protein
-
BRCA2 protein, human
-
Blood Glucose
-
Carcinoembryonic Antigen
-
Fatty Acids, Omega-3
-
Serum Albumin
-
C-Reactive Protein
-
Creatinine
-
gamma-Glutamyltransferase
-
Alanine Transaminase